Kendra Johnston1,2,3, Panayotis Pachnis3, Alpaslan Tasdogan3, Brandon Faubert3, Lauren G Zacharias3, Hieu Sy Vu3, Laurie Rodgers-Augustyniak2, Allison Johnson2, Fang Huang3, Sean Ricciardo2,4, Zhiyu Zhao3, Thomas P Mathews3, Tanya Watt1,2, Patrick Leavey1,2, Ralph J DeBerardinis1,3,5,6. 1. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 2. Children's Medical Center, Dallas, Texas 75235, USA. 3. Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 4. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 5. Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 6. Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Abstract
Background: Survival among children with high-risk solid tumors remains poor. Reprogrammed metabolism promotes tumor growth and may contain therapeutic liabilities. Tumor metabolism has been assessed in adults using intra-operative 13C-glucose infusions. Pediatric tumors differ from adult cancers in their low mutational burden and derivation from embryonic tissues. Here we used 13C infusions to examine tumor metabolism in children, comparing phenotypes among tumor types and between childhood and adult cancers. Methods: Patients recruited to study NCT03686566 received an intra-operative infusion of [U-13C]glucose during tumor resection to evaluate central carbon pathways in the tumor, with concurrent metabolomics to provide a broad overview of metabolism. Differential characteristics were determined using multiple comparison tests and mixed effect analyses. Findings: We studied 23 tumors from 22 patients. All tumors analyzed by [U-13C]glucose contained labeling in glycolytic and tricarboxylic acid (TCA) cycle intermediates. Labeling in the TCA cycle indicated activity of pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), with PDH predominating. Neuroblastomas had high lactate labeling relative to other childhood cancers and lung cancer, and were distinguished by abundant tyrosine catabolites consistent with catecholamine synthesis. Conclusions: Intra-operative [U13C]glucose infusions are safe and informative in pediatric cancer. Tumors of various histologies use glycolysis and oxidative metabolism, with subtype-selective differences evident from this small cohort. Expanding this cohort may uncover predictive biomarkers and therapeutic targets from tumor metabolism. Funding: N.C.I grants to P.L. (R21CA220090-01A1) and R.J.D. (R35CA22044901); H.H.M.I. funding to R.J.D.; Children's Clinical Research Advisory Committee funding to K.J.
Background: Survival among children with high-risk solid tumors remains poor. Reprogrammed metabolism promotes tumor growth and may contain therapeutic liabilities. Tumor metabolism has been assessed in adults using intra-operative 13C-glucose infusions. Pediatric tumors differ from adult cancers in their low mutational burden and derivation from embryonic tissues. Here we used 13C infusions to examine tumor metabolism in children, comparing phenotypes among tumor types and between childhood and adult cancers. Methods: Patients recruited to study NCT03686566 received an intra-operative infusion of [U-13C]glucose during tumor resection to evaluate central carbon pathways in the tumor, with concurrent metabolomics to provide a broad overview of metabolism. Differential characteristics were determined using multiple comparison tests and mixed effect analyses. Findings: We studied 23 tumors from 22 patients. All tumors analyzed by [U-13C]glucose contained labeling in glycolytic and tricarboxylic acid (TCA) cycle intermediates. Labeling in the TCA cycle indicated activity of pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), with PDH predominating. Neuroblastomas had high lactate labeling relative to other childhood cancers and lung cancer, and were distinguished by abundant tyrosine catabolites consistent with catecholamine synthesis. Conclusions: Intra-operative [U13C]glucose infusions are safe and informative in pediatric cancer. Tumors of various histologies use glycolysis and oxidative metabolism, with subtype-selective differences evident from this small cohort. Expanding this cohort may uncover predictive biomarkers and therapeutic targets from tumor metabolism. Funding: N.C.I grants to P.L. (R21CA220090-01A1) and R.J.D. (R35CA22044901); H.H.M.I. funding to R.J.D.; Children's Clinical Research Advisory Committee funding to K.J.
Authors: Pei-Hsuan Chen; Ling Cai; Kenneth Huffman; Chendong Yang; Jiyeon Kim; Brandon Faubert; Lindsey Boroughs; Bookyung Ko; Jessica Sudderth; Elizabeth A McMillan; Luc Girard; Dong Chen; Michael Peyton; Misty D Shields; Bo Yao; David S Shames; Hyun Seok Kim; Brenda Timmons; Ikuo Sekine; Rebecca Britt; Stephanie Weber; Lauren A Byers; John V Heymach; Jing Chen; Michael A White; John D Minna; Guanghua Xiao; Ralph J DeBerardinis Journal: Mol Cell Date: 2019-09-26 Impact factor: 17.970
Authors: Katherine K Matthay; John M Maris; Gudrun Schleiermacher; Akira Nakagawara; Crystal L Mackall; Lisa Diller; William A Weiss Journal: Nat Rev Dis Primers Date: 2016-11-10 Impact factor: 52.329
Authors: Elizabeth A Maher; Isaac Marin-Valencia; Robert M Bachoo; Tomoyuki Mashimo; Jack Raisanen; Kimmo J Hatanpaa; Ashish Jindal; F Mark Jeffrey; Changho Choi; Christopher Madden; Dana Mathews; Juan M Pascual; Bruce E Mickey; Craig R Malloy; Ralph J DeBerardinis Journal: NMR Biomed Date: 2012-03-15 Impact factor: 4.044
Authors: Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop Journal: Cell Metab Date: 2012-02-08 Impact factor: 27.287
Authors: Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter Journal: Mol Cancer Res Date: 2017-07-18 Impact factor: 5.852
Authors: Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton Journal: Genome Med Date: 2017-04-19 Impact factor: 11.117
Authors: Khoa Pham; Allison R Hanaford; Brad A Poore; Micah J Maxwell; Heather Sweeney; Akhila Parthasarathy; Jesse Alt; Rana Rais; Barbara S Slusher; Charles G Eberhart; Eric H Raabe Journal: Cancers (Basel) Date: 2022-03-03 Impact factor: 6.575
Authors: Jonathan M Ghergurovich; Jessica D Lang; Maren K Levin; Natalia Briones; Salvatore J Facista; Claudius Mueller; Alexis J Cowan; Matthew J McBride; Esther San Roman Rodriguez; Aaron Killian; Tuoc Dao; Jeffrey Lamont; Alison Barron; Xiaoyang Su; William P D Hendricks; Virginia Espina; Daniel D Von Hoff; Joyce O'Shaughnessy; Joshua D Rabinowitz Journal: Med (N Y) Date: 2021-04-14